Aifu Jifu (艾夫吉夫)艾夫吉夫
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 上海腾瑞制药有限公司Chinese legal name: 上海腾瑞制药有限公司
主要成分Active Ingredients
- 重组人酸性成纤维细胞生长因子Chongzu Rensuan Xingcheng Xianwei Xibao Shengzhang Yinzi
药物知识说明
重组人酸性成纤维细胞生长因子是一种在国家药监局注册认定的药品。标注生产企业为上海腾瑞制药有限公司。
该药品暂无关联的活性成分信息。
该药品标注的生产企业为：上海腾瑞制药有限公司Chinese legal name: 上海腾瑞制药有限公司、上海腾瑞制药有限公司Chinese legal name: 上海腾瑞制药有限公司、上海腾瑞制药有限公司Chinese legal name: 上海腾瑞制药有限公司。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 艾夫吉夫) is a medicine registered with the national drug regulatory authority. It is manufactured by Chinese legal name: 上海腾瑞制药有限公司.
No active ingredient relationships are currently recorded for this product in MedicineGraph.
Manufacturers recorded for this product: 上海腾瑞制药有限公司Chinese legal name: 上海腾瑞制药有限公司, 上海腾瑞制药有限公司Chinese legal name: 上海腾瑞制药有限公司, 上海腾瑞制药有限公司Chinese legal name: 上海腾瑞制药有限公司.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 艾夫吉夫Recorded Chinese name: 艾夫吉夫
- 规格Specification: 25000U/瓶，每瓶装量为2ml冻干粉。Recorded Chinese description: 25000U/瓶，每瓶装量为2ml冻干粉。
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
生产企业Manufacturer
- 上海腾瑞制药有限公司Chinese legal name: 上海腾瑞制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字S20060102
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字S20060102
Manufacturer
Chinese legal name: 上海腾瑞制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字S20060102
生产企业
上海腾瑞制药有限公司(国产)
适应症
本品用于下述创面，以促进创面愈合： 1深II度烧伤创面。 2慢性溃疡创面（包括外伤后残余创面、糖尿病溃疡、血管性溃疡和褥疮）。
用法用量
用法：将本包装中所配置的10ml溶媒倒入装有rhaFGF冻干粉的瓶中，盖（卡）上包装中所配置的喷雾器头后，即可开始使用。将药液直接喷于清创后的伤患处，或在伤患处覆以适当大小的消毒纱布，将药液均匀滴加于纱布，适当包扎即可。每日换药1次，或遵医嘱。对于烧伤创面，用药时间最长不宜超过3周；对于慢性溃疡创面，用药时间最长不宜超过6周。用量：本品最适用量约为：100U/cm2
不良反应
在本品的临床研究中，部分使用者出现了瘙痒、皮疹、轻微发热和创面疼痛，停药后并加抗过敏药物治疗，瘙痒和皮疹均消失。未发现有其他明显不良反应。
禁忌
对本品中任何成分过敏者禁用。
贮藏
2~8℃避光保存和运输。
规格
25000U/瓶，每瓶装量为2ml冻干粉。
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.